INFANTS via maternal immunisation *
ADULTS aged ≥60 years †
Recombinant respiratory syncytial virus pre-fusion F protein vaccine
2 INDICATIONS , 1 VACCINE 1 , 2
INFANTS via maternal immunisation *
ADULTS aged ≥60 years †
Recombinant respiratory syncytial virus pre-fusion F protein vaccine
EVERY
BREATH
MATTERS .
ABRYSVO is recommended in the Australian Immunisation Handbook to help protect both infants ,* via maternal immunisation , and adults aged ≥60 years † against respiratory syncytial virus ( RSV ). 2
* Active immunisation of pregnant women at 28 – 36 weeks gestation . 1 , 2
†
Active immunisation of adults aged ≥75 years , Aboriginal and Torres Strait Islander adults aged ≥60 years , and adults aged ≥60 years with risk factors for severe RSV disease . 1 , 2
2 Scan to view RSV
Now NIP-funded for pregnant n women recommendations
This vaccine is subject to additional monitoring in Australia . This will allow quick identification of new safety information . Healthcare professionals are asked to report any suspected adverse events at www . tga . gov . au / reporting-problems .
PBS Information : ABRYSVO is listed on the NIP for pregnant women ( 28 – 36 weeks gestation ) only and is not listed on the PBS .
Before prescribing , please review the Approved Product Information by scanning the QR code .
ABRYSVO should be used in accordance with official recommendations . 1 , 2
ABRYSVO ® ( recombinant respiratory syncytial virus pre-fusion F protein ) 120 micrograms / 0.5 mL bivalent vaccine powder for injection vial and diluent syringe
Indications : Active immunisation of pregnant women ( 24-36 weeks gestation ) for prevention of lower respiratory tract disease caused by RSV in infants ( birth through 6 months ); Active immunisation of individuals ( 60 years and above ) for prevention of lower respiratory tract disease caused by RSV . Use ABRYSVO in accordance with official recommendations . Contraindications : Hypersensitivity to the active ingredient or to any of the excipients . Precautions : Appropriate treatment and supervision must be readily available in case of a rare anaphylactic reaction . Consider the risks of intramuscular injection in thrombocytopenia or coagulation disorders . Postpone in acute febrile illness . Anxiety-related reactions including syncope can occur following / before any vaccination . Immunocompromised individuals , including individuals receiving immunosuppressant therapy , may have a diminished immune response . No studies in pregnant individuals < 24 weeks gestation . Protection may not be conferred in all individuals . Not for active immunisation in children . See PI for details . Interactions with other Medicines : Can be administered concomitantly , at different injection sites , with seasonal influenza vaccine and COVID-19 mRNA vaccines . Immunogenicity data indicated non-inferiority in immune response to RSV , diphtheria and tetanus components compared to ABRYSVO or dTpa administered alone . Immune response to the pertussis component of dTpa was lower in concomitant administration than dTpa administered alone . The clinical relevance of this is unknown . See PI for details . Adverse Effects : Headache , myalgia , vaccination site pain , vaccination site redness , vaccination site swelling , Guillain-Barré syndrome , hypersensitivity . See PI for details . Dosage and Administration : Single ( 0.5 mL ) dose . For intramuscular use only . See PI for details . V10324 .